AbCellera Biologics Earnings Estimates, EPS & Revenue | NASDAQ:ABCL

Comments

AbCellera Biologics Inc Earnings Estimates

ABCLNASDAQ

Trade with Public

$3.58

0.0150.42%

Last update: Mar 11, 11:55 AM

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

AbCellera Biologics Earnings Estimates, EPS & Revenue | NASDAQ:ABCL

AbCellera Biologics (ABCL) is scheduled to report Q1 earnings on May 7, 2026. Analysts estimate EPS of $-0.20 and quarterly revenue of $5.95M.

In the most recent quarter (Q4), AbCellera Biologics reported EPS of $-0.03, beating estimates of $-0.18 by 0.83%. Revenue came in at $44.90M, exceeding the estimate of $6.72M by 5.68%.

Over the last 4 quarters, AbCellera Biologics has averaged an EPS surprise of 0.33% and a revenue surprise of 2.02%.

Earnings Date

May 7

EPS Estimate

$-0.200

Quarterly Revenue Estimate

$5.95M

Annual Revenue
(as of Dec 31)

$75.13M

AbCellera Biologics Earnings History

Analyze the earnings history of AbCellera Biologics using advanced sorting and filters.

AbCellera Biologics (ABCL) Earnings Per Share

The chart below shows AbCellera Biologics's reported EPS compared to analyst estimates over recent quarters.

AbCellera Biologics (ABCL) Revenue

The chart below shows AbCellera Biologics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is AbCellera Biologics (NASDAQ:ABCL) reporting earnings?

AbCellera Biologics (ABCL) is scheduled to report earnings on May 7, 2026. The last reported earnings were for reported on February 24, 2026 for Q4.

What were the latest earnings per share (EPS) for AbCellera Biologics (NASDAQ:ABCL)?

The Actual EPS was $-0.03, which beat the estimate of $-0.18.

What were AbCellera Biologics’s (NASDAQ:ABCL) revenues?

The Actual Revenue was $44.90M, which beat the estimate of $6.72M.

People Also Watch

Agilent Technologies Inc

AbCellera Biologics Earnings Estimates, EPS & Revenue | NASDAQ:ABCL

AbCellera Biologics (ABCL) is scheduled to report Q1 earnings on May 7, 2026. Analysts estimate EPS of $-0.20 and quarterly revenue of $5.95M.

In the most recent quarter (Q4), AbCellera Biologics reported EPS of $-0.03, beating estimates of $-0.18 by 0.83%. Revenue came in at $44.90M, exceeding the estimate of $6.72M by 5.68%.

Over the last 4 quarters, AbCellera Biologics has averaged an EPS surprise of 0.33% and a revenue surprise of 2.02%.

Earnings Date

May 7

EPS Estimate

$-0.200

Quarterly Revenue Estimate

$5.95M

Annual Revenue
(as of Dec 31)

$75.13M